Haemophilus influenzae in respiratory tract infections in community-based clinical practice: Therapy with gatifloxacin

Diagnostic Microbiology and Infectious Disease

Volumn 44, Issue 1, 2002, Pages 101-107

  Nicholson, Susan C ^a,b   Webb, C Douglas ^a   Andriole, Vincent T ^c   Jones, Ronald N ^d   Wilson, Walter R ^e  

^a BRISTOL MYERS SQUIBB   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JMI LABORATORIES   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Gatifloxacin; Haemophilus influenzae; Respiratory tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; EMPIRICISM; FEMALE; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHYSICAL DISEASE BY BODY FUNCTION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 0036743899     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00449-2     Document Type: Article

References (34)

1. Adams S.G., Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Seminars Respiratory Infection. 15:2000;234-247.
2. Ball P., Make B. Acute exacerbations of chronic bronchitis. An international comparison. Chest. 113:1998;199S-204S.
3. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr, Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clinical Infectious Disease. 31:2000;347-382.
4. Blondeau J.M. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. Journal of Antimicrobial Chemotherapy. 43:(Suppl B):1999;1-11.
5. Centers for Disease Control and Prevention . Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children - United States, 1998-2000. MMWR. 51:2002;234-237.
6. Chodosh S., Schreurs A., Siami G., Barkman H.W. Jr, Anzueto A., Shan M., Moesker H., Stack T., Kowalsky S. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clinical Infectious Disease. 27:1998;740-748.
7. Craig W.A. Re-evaluating current antibiotic therapy. Respiratory Medicine. 95:(Suppl. A):2001;S12-S19.
8. Dagan R., Leibovitz E., Greenberg D., Yagupsky P., Fliss D.M., Leiberman A. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatric Infectious Disease Journal. 17:1998;776-782.
9. Dagan R., Johnson C.E., McLinn S., Abughali N., Feris J., Leibovitz E., Burch D.J., Jacobs M.R. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatric Infectious Disease Journal. 19:2000;95-104.
10. Dagan R. Clinical significance of resistant organisms in otitis media. Pediatric Infectious Disease Journal. 19:2000;378-382.
11. File T.M. Jr, Tan J.S. Incidence, etiologic pathogens, and diagnostic testing of community acquired pneumonia. Current Opininions in Pulmonary Medicine. 3:1997;89-97.
12. Frick A.G., Joseph T.D., Pang L., Rabe A.M., St. Geme J.W. III, Look D.C. Haemophilus influenzae stimulates ICAM-1 expression on respiratory epithelial cells. Journal of Immunology. 164:2000;4185-4196.
13. Fung-Tomc J., Minassian B., Kolek B., Washo T., Huczko E., Bonner D. In vitro antibacterial spectrum of a broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. Journal of Antimicrobial Chemotherapy. 45:2000;437-446.
14. Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease National Heart, Lung, and Blood Institute/World Health Organization workshop report . 2000;. Available at: http://www.goldcopd.com. Accessed April 16.
15. Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Pankuch G.A., Appelbaum P.C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters 1997 U.S. surveillance study . Antimicrobial Agents and Chemotherapy. 43:1999;1901-1908.
16. Jones R.N. The impact of antimicrobial resistance Changing epidemiology of community-acquired respiratory-tract infections . American Journal of Health-System Pharmacology. 56:(Suppl. 3):1999;S4-S11.
17. Jones R.N., Biedenbach D.J., Erwin M.E., Beach M.L., Pfaller M.A., Quality Control Study Group . Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. Journal of Clinical Microbiology. 37:1999;1999-2002.
18. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY Antimicrobial Surveillance Program. Clinical Infectious Disease. 31:(Suppl. 2):2000;S16-S23.
19. Lister P.D. Emerging resistance problems among respiratory tract pathogens. American Journal of Management Care. 6:(Suppl.):2000;S409-S418.
20. Mandell L.A., Marrie T.J., Grossman R.F., Chow A.W., Hyland R.H., Canadian Community-Acquired Pneumonia Working Group . Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clinical Infectious Disease. 31:2000;383-421.
21. Moxon E.R., Murphy T.F. Haemophilus influenzae. Mandell G.L., Bennett J.E., Dolin R., Principles and Practices of Infectious Diseases. 5th ed. 2000;2369-2378 Churchill Livingstone, New York.
22. National Committee for Clinical Laboratory Standards . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard. 4th ed. 2000;NCCLS, Wayne, PA.
23. National Committee for Clinical Laboratory Standards . Performance standards for antimicrobial susceptibility testing - Twelfth International Supplement M100-S12. 2002;NCCLS, Wayne, PA.
24. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., Dean N., File T., Fine M.J., Gross P.A., Martinez F., Torres A., Wilson R., Yu V.L. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Journal of Respiratory and Critical Care Medicine. 163:2001;1730-1754.
25. Pfaller M.A., Jones R.N. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program study microbiology from the medical office practice environment . American Journal of Medicine. 111:(Suppl. 1):2001;4-12.
26. Richter S.S., Brueggemann A.B., Huynh H.K., Rhomberg P.R., Wingert E.M., Flamm R., Doern G.V. A 1997-1998 national surveillance study Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions . International Journal of Antimicrobial Agents. 13:1999;99-107.
27. Schmitz F.-J., Verhoef J., Fluit A.C., SENTRY Participants Group . Comparative activities of six different fluoroquinolones against 9,692 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. International Journal of Antimicrobial Agents. 12:1999;311-317.
28. Seaton R.A., Steinke D.T., Phillips G., MacDonald T., Davey P.G. Community antibiotic therapy, hospitalization and subsequent respiratory tract isolation of Haemophilus influenzae resistant to amoxycillin a nested case-control study . Journal of Antimicrobial Chemotherapy. 46:2000;307-309.
29. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 117:2000;380S-385S.
30. Sethi S. Infectious exacerbations of chronic bronchitis Diagnosis and management . Journal of Antimicrobial Chemotherapy. 43:(Suppl. A):2000;97-105.
31. Smayevsky J., Lopez H., Di Chiara M., Scarano S., Lanza A., Vilches V., Stepanito D., Bantar C., Sucari A. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection. Diagnostic Microbiology and Infectious Disease. 37:2000;261-264.
32. Thornsberry C., Jones M.E., Hickey M.L., Mauriz Y., Kahn J., Sahm D.F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in the United States, 1997-1998. Journal of Antimicrobial Chemotherapy. 44:1999;749-759.
33. Von Seggern K., Russo R., Wikler M.A. A novel approach to postmarketing surveillance the Tequin Clinical Experience Study . In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000;American Society for Microbiology, Washington, DC.
34. Zhanel G.G., Karlowsky J.A., Low D.E., Canadian Respiratory Infection Study Group, Hoban D.J. Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998. Journal of Antimicrobial Chemotherapy. 45:2000;655-662.